## **MAKING SCIENCE**

## Ventis prompts cut in estimates post Q3

- Q3 results below. Q3 revenues and adj. EBITDA jumped by c.90% YoY to €52m and €2m respectively. Both came below our €58m and €2.7m estimates, mainly on a weaker Ventis. Reported EBITDA was €1.6m below our €2.5m.
- Core business growth within ambitious targets. Core business revenues doubled YoY to €50m: a) Spain grew by 34% purely organically to €29m (57% of the total) driven by new client gains and upselling; b) International rocketed by >4X, mainly on M&A (Tre Kronor in Sweden was the largest contributor). Adj. EBITDA reached €2.5m, +60%, slightly below our €2.7m estimate due to greater than expected personnel investments. As of 9M, adj. EBITDA grew by 31% organically, within the group's 25-40% ambitious growth range target.
- Ventis: the weak spot. Ventis (ecommerce) sales stood flat YoY at €2.3m, below our €3m, due to a greater than expected impact of the weakening consumer demand. Gross profit jumped by 25% YoY thanks to the different profitability measures being applied ("just" 15% below estimates) but adj. EBITDA was flat at -€0.5m, below our -€0.1m estimate. Making Science expects Q4 sales to account for 45-50% of FY22 revenues due to seasonality.
- Debt higher than expected. H1 ND was €29m, +€6m vs. FY21 and higher than our €22m estimate, €5m explained by WC (-€5m vs. our €0m, which we think is temporary and should reverse in H2) and €2m on higher capex & lower EBITDA.
- New M&A halted. Making Science is in advanced conversations with potential M&A targets. However, in view of the worsening economic environment, MKS said that it is prioritising being prudent financially, and does not expect to fulfil its M&A targets (up to €7m of new inorganic EBITDA) before YE.
- Cutting estimates. We are trimming our core business EBITDA by c.3% p.a. to reflect a weaker economic environment (our FY22 EBITDA growth sits in the lower end of the guidance range). For Ventis, we are slashing our 2022 EBITDA from -€0.7m to -€1.5m and we expect EBITDA breakeven one year later, i.e., in 2024. Both effects combined lead us to cut our 2022-24 EBITDA by 8-11% p.a. This, together with higher D&A and financial expenses leads us to cut our adj. EPS 25-30%. The challenges for the Ventis platform are increasing and cloud the steady and strong growth at the core business (85% of group EV). Likewise, we think that it makes sense for MAKS to be extra cautious on the M&A front until the company has better visibility on its operations and valuations of M&A targets start to reflect a weaker economic prospect.

Financial Ratios	FY19	FY20	FY21	FY22E	FY23E	FY24E
EBITDA (€m)	2.4	3.7	5.7	9.3	11.7	14.3
Net profit (€m)	0.7	1.5	(3.5)	(1.3)	0.9	3.1
EPS (€)	0.10	0.22	(0.45)	(0.16)	0.10	0.37
Adj. EPS (*) (€)	0.28	0.39	0.45	0.38	0.58	0.82
P/E (x)		33.8	n.a	n.a.	114.1	32.6
P/E Adj. (x)		19.2	56.1	31.6	20.5	14.6
EV/EBITDA (x)		14.8	38.7	13.8	10.5	8.1
Debt/EBITDA (x)	0.5	0.7	4.1	2.4	1.5	0.7
P/BV (x)		18.1	18.7	4.8	4.6	4.0
ROE (%)		53.6	(33.2)	n.a.	4.0	12.4
DPS (€)	0.0	0.0	0.0	0.00	0.00	0.00
Dividend yield (%) (*) Historical multiples bas	0.0 ed on average sh	0.0 are price of the	0.0 year	0.0	0.0	0.0

### SPONSORED RESEARCH

Share Price (*)	€ 11.95
*Share price at the close o	f 28 October 2022

MAKS.MC/	
Market Cap	€ 96 m
Enterprise Value	€ 124 m
Free Float	€ 22 m
Nº Shares	8 m
Average Daily Volume	€7 k





Analyst
Fernando Abril-Martorell
+34 91 550 87 19

fabrilmartorell@alantraequities.com

### Making Science

# ALANTRA Equities

MAKING SCIENCE: QUA	RTERLY P&L	REVIEW						
(€ m)	3Q21	4Q21	1Q22	2Q22	3Q22	% YoY	3Q22E	% diff
Revenues	27.3	35.3	39.7	58.4	51.8	89%	58.0	(11%)
o/w core business	25.1	31.4	36.1	56.0	49.5	97%	55.0	(10%)
o/w Ventis	2.2	3.9	3.6	2.4	2.3	2%	3.0	(24%)
Gross Profit	7.4	8.5	11.8	13.9	14.0	89%	14.5	(3%)
o/w core business	6.9	9.0	11.3	12.8	13.4	94%	13.7	(2%)
o/w Ventis	0.5	(0.5)	0.5	1.1	0.7	25%	0.8	(17%)
Own work capitalised	0.7	0.6	0.8	0.9	0.6	(9%)	0.9	(29%)
Personnel	(5.1)	(6.5)	(7.3)	(8.3)	(9.3)	83%	(8.2)	13%
Opex	(2.3)	(2.5)	(3.6)	(4.4)	(3.8)	69%	(4.0)	(4%)
EBITDA	0.8	0.1	1.6	2.1	1.6	99%	2.4	(33%)
One-offs	(0.2)	(1.0)	(0.4)	(0.3)	(0.4)	66%	(0.2)	78%
Adj. EBITDA	1.0	1.1	2.0	2.4	2.0	92%	2.6	(25%)
o/w core business	1.5	1.9	2.5	2.8	2.5	67%	2.7	(7%)
o/w Ventis	(0.5)	(0.8)	(0.5)	(0.4)	(0.6)	16%	(0.1)	n.m.

Source: Alantra Equities

### Making Science

## ALANTRA Equities

KEY DATA															
P&L account (€ m)	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E	Cash flow (€ m)	FY18	FY19	FY20	FY21	FY22E	FY23E	FY
Revenue	18.8	34.6	57.7	110.4	216.2	244.0	277.7	Net profit	(2.4)	0.7	1.5	(3.5)	(1.3)	0.9	
COGS	(9.8)	(26.1)	(42.9)	(80.4)	(161.7)	(180.5)	(205.2)	Depreciation	0.1	0.4	0.9	3.8	6.7	7.1	
Gross margin	9.0	8.4	14.8	30.0	54.6	63.5	72.5	Minorities	-	-	-	0.3	0.5	0.6	
Opex	(7.5)	(7.1)	(11.3)	(27.7)	(46.6)	(52.5)	(58.5)	Non-cash adjustments	2.8	0.1	0.7	(0.2)	(0.0)	0.0	
EBITDA	1.5	1.4	3.5	2.4	8.0	11.0	14.0	Total cash-flow (CF)	0.5	1.2	3.1	0.5	5.9	8.6	
One-offs	0.1	1.0	0.2	3.4	1.3	0.7	0.3	Capex	(0.4)	(0.8)	(1.2)	(2.5)	(4.0)	(3.2)	
Adj. EBITDA	1.6	2.4	3.7	5.7	9.3	11.7	14.3	Working capital investment	1.3	0.7	0.5	5.8	0.2	0.3	
D&A	(0.1)	(0.4)	(0.9)	(3.8)	(6.7)	(7.1)	(7.5)	Operating FCF	1.5	1.1	2.4	3.7	2.1	5.7	
Provisions & Other	(3.5)	(0.0)	-	(0.0)	-	-	-	Financial investments	-	-	-	-	-	-	
EBIT	(2.1)	0.9	2.6	(1.5)	1.2	3.9	6.5	Disposals (acquisitions)	-	(0.7)	(5.0)	(34.9)	(12.4)	(1.0)	
Net financials	(0.1)	0.0	0.0	0.0	(2.2)	(2.1)	(1.8)	Other	-	-	-	-	-	-	
Equity method & other	-	(0.1)	(0.5)	(1.1)	-	-	-	Dividends to minorities	-	-	-	-	-	-	
EBT	(2.2)	0.8	2.1	(2.5)	(1.0)	1.8	4.7	Rights issues	-	-	1.2	10.6	11.8	-	
Income tax expense	(0.2)	(0.1)	(0.5)	(0.7)	0.2	(0.4)	(0.9)	Free-cash-flow (FCF)	1.5	0.4	(1.5)	(20.5)	1.4	4.7	
Minorities	-	-	-	(0.3)	(0.5)	(0.6)	(0.7)	Dividends paid	-	-	-		-	-	
Net profit, reported	(2.4)	0.7	1.5	(3.5)	(1.3)	0.9	3.1	Share buybacks	-	-		-	-	-	
Adjustments	3.6	1.2	1.2	7.0	4.5	4.0	3.8	FCF after buy backs	1.5	0.4	(1.5)	(20.5)	1.4	4.7	
Net profit adjusted	1.2	1.8	2.7	3.5	3.2	4.9	6.9								
								Balance sheet (€ m)	FY18	FY19	FY20	FY21	FY22E	FY23E	F
№ of shares (m)	4.0	6.7	7.1	7.8	8.4	8.4	8.4	Shareholders equity	1	0	3	11	21	22	_
№ of shares adjusted (m)	4.0	6.4	6.8	7.6	8.2	8.2	8.2	Minorities	-	-		1	5	5	
Treasury stock (m)		0.3	0.3	0.2	0.2	0.2	0.2	Provisions & others	3	2	5	5	5	5	
								Net debt (cash)	2	1	3	23	22	17	
YoY Growth	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E	Capital invested	5	4	10	40	53	50	
Sales	40%	83%	67%	92%	96%	13%	14%								
EBITDA	36%	(9%)	153%	(32%)	238%	39%	27%	Other intangible	3	5	11	40	52	49	
Adj. EBITDA	46%	49%	54%	55%	62%	26%	23%	PP&E	0	0	0	1	1	1	
ЕВІТ	(290%)	(142%)	193%	(158%)	(183%)	220%	65%	Financial assets	0	0	0	1	1	1	
Net profit	n.m.	(128%)	132%	n.m.	(62%)	(167%)	250%	Equity method	3	0	0	0	0	0	
		(,-)			(	(,		Working capital	(1)	(2)	(1)	(2)	(2)	(2)	
Sales by division	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E	Capital employed	5	4	10	40	53	50	
Core Business	100%	100%	100%	94%	93%	93%	93%	Working capital/sales	(6.4%)	(5.5%)	(2.1%)	(1.4%)	(0.8%)	(0.8%)	(0
E-commerce	0%	0%	0%	6%	7%	7%	7%		(0.1.70)	(0.070)	()	(,,,,	()	()	
	0,0	0,0	0,0	070	170	. ,0	170	Financial ratios	FY18	FY19	FY20	FY21	FY22E	FY23E	F
EBITDA by division	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E	Net debt/EBITDA	1.1X	0.9X	0.8X	9.9X	2.7X	1.5X	-
Core Business	100%	100%	100%	124%	116%	107%	101%	Net debt/Adj. EBITDA	1.0X	0.5X	0.7X	4.1X	2.4X	1.5X	
E-commerce	0%	0%	0%	(24%)	(16%)	(7%)	(1%)	Gearing	222%	283%	95%	222%	104%	78%	
E-connerce	078	078	078	(2470)	(10%)	(776)	(170)	Interest cover		(301.2X)		199.1X	0.6X	1.9X	
Der ohere dete	EV49	5740	57.20	57.24	EVODE	EVO2E	EVOAE	interest cover	(20.37)	(301.27)	(101.77)	199.17	0.07	1.57	
Per share data	FY18	FY19	FY20	FY21	FY22E	FY23E	FY24E	Margina 9 rott	EV44	EV40	EVee	EVA	EVOOF	EVODE	
EPS	(0.60)	0.10	0.22	(0.45)	(0.16)	0.10	0.37	Margins & ratios	FY18	FY19	FY20	FY21	FY22E	FY23E	F
EPS adjusted	0.29	0.28	0.39	0.45	0.38	0.58	0.82	EBITDA margin	8%	4%	6%	2%	4%	5%	
CFPS	0.12	0.18	0.44	0.06	0.70	1.02	1.34	Effective tax rate	11%	(14%)	(26%)	26%	(20%)	(20%)	(
FCFPS	0.36	0.16	0.34	0.48	0.25	0.68	1.03	Pay-out	0%	0%	0%	0%	0%	0%	
BVPS	0.19	0.07	0.41	1.35	2.49	2.59	2.96	ROCE (EBIT/CE)	(40%)	23%	25%	(4%)	2%	8%	
DPS	-	-	-	-	-	-	-	ROE	n.a.	151%	54%	n.a.	n.a.	4%	

Alantra Equities: This report (the "Report") has been prepared by Alantra Equities Sociedad de Valores, S.A. ("Alantra Equities"), a company pertaining to the Alantra Group that provides investment banking, asset management, equities brokerage, capital markets and financial advisory services. The date and hour of preparation of this investment recommendation refers to the date and hour of preparation and disclosure indicated on the first page of the Report.

Alantra Equities Sociedad de Valores, S.A. is a Spanish investment firm located in Madrid, calle José Ortega y Gasset 29, registered at the Comisión Nacional del Mercado de Valores (CNMV) with number 245.

Analyst certification: Each research analyst primarily responsible for the content of this research Report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this Report: (i) all the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, and (ii) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that research analyst in this research Report.

#### Important disclosures:

Alantra Equities receives remuneration from the issuer that this Report refers to in consideration of the research services that Alantra Equities provides to it. Therefore, this Report is considered sponsored research or marketing material for the purposes of the provisions of the Markets in Financial Instruments Directive.

#### Within the last 12 months, Alantra Equities is participating as co-global coordinator in connection with the capital increase of Making Science Group S.A.

This Report is solely for the information of clients of Alantra Equities and for distribution only under such circumstances as may be permitted by applicable law. Alantra Equities specifically prohibits the redistribution of this material in whole or in part without the prior written permission of Alantra Equities and therefore Alantra Equities accepts no liability whatsoever for the actions or third parties in this respect.

The opinions contained in this report and in other media used by Alantra Equities (such as the internet), reflect the opinion of the respective Analyst on the date of publication of such material and, therefore, may be subject to change at any time and without notice.

Nothing in this Report constitutes a representation that any investment strategy or recommendation contained herein is suitable or appropriate to a recipient's individual circumstances or otherwise constitutes a personal recommendation. This Report is published solely for information purposes, it does not constitute an advertisement and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments in any jurisdiction. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, nor it is intended to be a complete statement or summary of the securities or markets referred to in this Report. Alantra Equities does not undertake that investors will obtain profits nor accept any liability for any investment losses arising from any use of this Report or its contents. Investments involve risks and investors should exercise prudence in making their investment decisions. This Report should not be regarded by recipients as a substitute for the exercise of their own judgement. Any opinions expressed in this Report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas of the Alantra Group as a result of using different assumptions and criteria. Research will be initiated, updated and coverage ceased solely at the discretion of Alantra Equities. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. Alantra Equities is under no obligation to keep current the information contained in this Report.

The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this Report.

Any prices stated in this Report are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effected at those prices.

Neither Alantra Equities nor any of the companies pertaining to the Alantra Group nor any of their shareholders, directors, employees or agents accept any liability for any loss or damage arising out of the use of all or any part of this Report.

Except as otherwise specified herein, this material is communicated by Alantra Equities to persons who are eligible counterparties or professional clients and is only available to such persons. The information contained herein does not apply to retail clients.

#### Important disclosures on conflicts of interest:

The analysts responsible for the preparation of this Report may interact with trading desk personnel, sales personnel and investment managers. Alantra Equities belongs to the Alantra Group, a group that is engaged in financial advisory services, asset management as well as securities trading and brokerage, and capital markets. Alantra Equities, any other company pertaining to the Alantra Group, and any of their shareholders, directors, employees may, to the extent permitted by law, have a position or otherwise be interested in any transactions, in any investments directly or indirectly the subject of this publication. The Alantra Group relies on information barriers to control the flow of information contained in one or more areas within the Alantra Group, into other areas, units, groups or affiliates of the Alantra Group. The Alantra Group may do and seek to do business with companies covered in its research reports. As a result, investors should be aware that the Alantra Group may have a conflict of interest.

For the purposes of mitigating any conflict of interests, the Alantra Group has established, implemented and maintains an effective conflicts of interest policy appropriate to its size and organisation and to the nature, scale and complexity of its business. The policy, periodically revised, can be consulted at the Alantra Equities website through the following link: Conflicts of Interest. Investors should consider this Report as only a single factor in making their investment decisions. In addition, Alantra Group's website (www.alantra.com) provides information on closed and public corporate transactions, not subject to confidentiality, in which the Alantra Group, through its subsidiaries in the investment banking area, has acted as financial advisor, from time to time.

The disclosures contained in research Report produced by Alantra Equities shall be governed by and construed in accordance with Spanish law.

The receipt of this Report implies full acceptance by its recipients of the contents of this disclaimer.